Finance

Beta
Lists
RNA:NASDAQ
Atrium Therapeutics Inc
$13.19
+3.21%
(+0.41) 1D
$13.19
-0.00% (-0.00020)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RNA...
Open
$12.78
High
$13.20
Low
$12.72
Mkt. cap
225.62M
Avg. vol.
203.44K
Volume
758.71K
52-wk high
$73.06
52-wk low
$11.40
Shares outstanding
36.14M
No. of employees
47
Open
$12.78
High
$13.20
Low
$12.72
Mkt. cap
225.62M
Avg. vol.
203.44K
Volume
758.71K
52-wk high
$73.06
52-wk low
$11.40
Shares outstanding
36.14M
No. of employees
47
News stories
From sources across the web
About Atrium Therapeutics Inc
CEO-
Employees47
Founded2025
Headquarters-
SectorBiotechnology
Websiteatriumtherapeutics.com
Analyst ratings
Based on 2 analysts giving stock ratings to RNA in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for RNA in the last 3 months.
Highest
Current $13.19
$25.00 (+89.54%)
Average
$25.00 (+89.54%)
Lowest
$25.00 (+89.54%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Siffringer
Cantor Fitzgerald
Buy
Initiated
$25.00
+89.5%
06/18/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Initiated
$25.00
+89.5%
06/18/2026
Joseph Schwartz
Leerink Partners
Buy
Initiated
$25.00
+89.5%
05/15/2026
Yanan Zhu
Wells Fargo
Buy
Initiated
$25.00
+89.5%
03/11/2026
Last report
May 14, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.97 / -
0.00%miss
Revenue / Est. (USD)
19.64M / 2.00M
+881.75%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Dec 2024
Mar 2025
Dec 2025
Mar 2026
Revenue
2.97M
1.57M
859.00K
19.64M
Cost of goods sold
7.52M
6.32M
14.29M
10.80M
Cost of revenue
7.52M
6.32M
14.29M
10.80M
Research and development expenses
-
622.00K
-
5.86M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.70M
2.09M
15.67M
20.26M
Operating expense
1.70M
2.71M
15.67M
26.12M
Total operating expenses
9.22M
9.02M
29.96M
36.92M
Operating income
-6.25M
-7.45M
-29.10M
-17.28M
Other non operating income
4.00K
3.00K
-
647.00K
EBT including unusual items
-6.25M
-7.45M
-29.10M
-16.63M
EBT excluding unusual items
-6.25M
-7.45M
-29.10M
-16.63M
Income tax expense
5.26M
-
34.00K
-
Effective tax rate
-84.28%
-
-0.12%
-
Other operating expenses
-
-
-
-
Net income
-11.51M
-7.45M
-29.14M
-16.63M
Net profit margin
-387.22%
-473.55%
-3,391.85%
-84.71%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.19M
-7.40M
-28.98M
-17.13M
Gain or loss from assets sale
-
-
140.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of RNA
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer